Zinc Supplementation in Alcoholic Cirrhosis

Not Applicable

Completed

• Conditions: Alcoholic Cirrhosis
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: Zinc

• Registration Number: NCT02072746
• Lead Sponsor: University of Louisville

Brief Summary

The purpose of this study is to determine if zinc therapy: (1) strengthens your intestine's defensive barrier preventing damaging substances from reaching your liver, (2) decreases liver injury (inflammation, oxidative stress, cell death) and scarring, and (3) improves your liver-related health. Based on our preliminary animal data and other published reports, we expect zinc therapy to achieve all of these goals. Zinc is affordable, available over the counter or by prescription, and has an excellent safety profile. Positive results from this study will show that zinc is a significant therapy for millions of Americans with alcoholic liver disease.

Detailed Description

Two-thirds of Americans consume alcohol, and an estimated 14 million Americans are alcoholics. It has been estimated that 15%-30% of heavy drinkers develop advanced Alcoholic liver disease (ALD). The prevalence of ALD in the United States is conservatively estimated at 2 million persons. Nearly 50% of liver-related deaths and 30% of hepatocellular carcinomas in the US are due to alcoholic cirrhosis. Despite recent advances in our understanding of ALD, there is currently no FDA approved medication for any stage of ALD. Zinc sulfate is inexpensive, available over the counter, and has an excellent safety profile. If zinc positively influences the mechanisms postulated to play a role in human ALD, this affordable treatment would become relevant to millions of people worldwide.

Study Timeline

• Study Start: 2010-02
• Primary Completion: 2011-03-01
• Study First Submitted: 2014-02-19
• Study First Submitted QC: 2014-02-26
• Study First Posted: 2014-02-27
• Study Completion: 2019-03-01
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-17
• Last Update Posted: 2021-03-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Ability to provide informed consent.
2. Clinical diagnosis of alcoholic cirrhosis.
3. Between the ages of 18 years and 70 years.
4. Ability to attend all clinic visits and participate in monthly telephone calls.
5. Child-Pugh score of A or B.

Exclusion Criteria

1. Allergy or intolerance to zinc sulfate.
2. Hospitalization within the previous 28 days.
3. Pregnancy.
4. Illicit drug use within the past 12 months.
5. Infection with hepatitis B, hepatitis C, or HIV.
6. Known or suspected cancer within the past 5 years.
7. Serum creatinine greater than 1.5 mg/dl within the past month.
8. Any severe chronic disease other than liver disease.
9. Impairment (slowness) of behavior, intelligence, and neuromuscular function which may indicate hepatic encephalopathy (slow or confused thinking due to your liver disease).
10. Participation in another clinical trial.
11. Any type of infection within the past month.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo study for comparison
Zinc	Zinc	zinc sulfate 220 mg daily

Primary Outcome Measures

Name	Time	Method
Change in clinical status	Baseline to 3 months	Whether the subject has improved clinically at time point.

Secondary Outcome Measures

Name	Time	Method
Blood zinc levels	0,3,6,12,24 months
Change in serum endotoxin levels	0,3,6,12,24 months	Whether the subject has a change in the serum endotoxin levels.

Trial Locations

Locations (1)

University of Louisville; 🇺🇸 Louisville, Kentucky, United States